Safety profiles of cyclosporine and tacrolimus in pregnancy: a pharmacovigilance analysis using the FDA Adverse Event Reporting System
Background The increasing use of calcineurin inhibitors (CNIs) among pregnant women highlights the importance of continuous safety surveillance. This study aimed to characterize the real-world safety signals of cyclosporine (CsA) and tacrolimus (TAC) during pregnancy using data from the FDA Adverse Event Reporting Syst...